A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)

    Not Recruiting
  • End date
    Nov 29, 2025
  • participants needed
  • sponsor
    Xencor, Inc.
Updated on 13 June 2022
combination therapy
monoclonal antibodies
squamous cell carcinoma
programmed cell death 1 ligand 1
solid tumors
solid tumour
solid tumor
squamous cell carcinoma of the head and neck
ovarian cancer
hepatocellular carcinoma
progesterone receptor
estrogen receptor
breast carcinoma
fallopian tube
squamous cell carcinoma of head and neck
transitional cell carcinoma
ovarian epithelial cancer
adenocarcinoma of prostate
cervical carcinoma
nasopharyngeal carcinoma
head and neck carcinoma
peritoneal cancer
primary peritoneal carcinoma
ovarian epithelial carcinoma
cancer of the ovary
fallopian tube cancer
epithelial ovarian cancer
lung carcinoma
gastroesophageal junction adenocarcinoma
bispecific antibody
urothelial carcinoma


This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.

Condition Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Treatment XmAb®22841, Pembrolizumab (Keytruda®)
Clinical Study IdentifierNCT03849469
SponsorXencor, Inc.
Last Modified on13 June 2022

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note